ORLANDO — According to research data presented at the Advances in Inflammatory Bowel Disease annual conference, skin protective counseling is inadequate among immune-suppressed patients with inflammatory bowel disease.
“Potential adverse effects of immune-suppressing medications require patient education and counseling,” Marie L. Borum, MD, EdD, MPH, division of gastroenterology and liver diseases, George Washington University, Washington, D.C., and colleagues wrote. “It is recommended that individuals with IBD who are treated with immunosuppressants be counseled regarding preventative measures to reduce their risk of skin cancer.”
In this retrospective study, researchers aimed to understand the differences between physician counseling practices regarding risk for skin cancer by collecting and analyzing clinical of 136 patients with chronic IBD seen at an urban medical center for 1 year.
“IBD patients are at an increased risk for skin cancers. This risk may be related to the underlying disease, medications or both,” the researchers wrote.
Of the patients, 27.9% were on immunomodulator therapy (n = 38), of which 28 were on monotherapy and 10 were on combined immunomodulator and biologic therapy. Approximately 12% of patients were on biologics alone (n = 17) and 81 patients were neither immunomodulator or biologic.
Overall, 32% of patients who received immunomodulator therapy, 80% on a immunomodulator/biologics combination therapy, 41% on biologic therapy only and 27% on neither, received skin protection counselling.
“This study revealed that [less than] 50% of patients had documented counseling regarding skin protective activities,” the researchers concluded. “While this study is limited due to size and single institution design, it suggests that increased efforts should be made to enhance counseling about skin cancer risk to optimize IBD patient care.” – by Melinda Stevens
Reference: Waseem N, et al. Abstract P-093. Presented at Advances in Inflammatory Bowel Diseases; Dec. 10-12, 2015; Orlando, Fla.
Disclosures: Healio Gastroenterology was unable to confirm relevant financial disclosures at the time of publication.